Intensity Share Price

Intensity Share Price

NASDAQ: INTS | Micro Cap | Healthcare
$2.57
+$2.57 (--%) Last updated on 18 Nov, 2026 | 23:57 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Intensity Stock Performance

Open
$2.66
Prev. Close
N/A
Circuit Range
N/A
Day Range
$2.60 - $2.66
Year Range
$0.22 - $7.99
Volume
701
Average Traded
$2.65

Intensity Share Price Chart

Line chart of the Intensity price trend over the selected period. The price rose overall, ranging from 2.57 to 2.66, ending at 2.57.
$2.60$2.66
L
Show Current Price
H

Intensity Stock Fundamentals & Key Indicators

Market Cap
$3.49M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-3.65
Revenue (TTM)
$0.00
Return On Equity (TTM)
-157.29%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-16.07%

Intensity Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$3.05-$2.43-$3.01-$3.54
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A20.33%-23.87%-17.61%

Intensity Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$7.58-$11.86-$16.27-$11.61
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-56.46%-37.18%28.64%

Intensity Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets1.391.421.830.31
Current Assets12.713.3615.461.45
Total Assets14.14.7817.31.76
Non Current Liabilities0.080.110.170.04
Current Liabilities2.151.763.966.82
Total Liabilities2.231.874.136.86
Shareholders' Equity11.882.9213.16-15.1

Intensity Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-9.23-15.22-7.21-5.48
Investing0.06.35-6.020.0
Financing18.562.920.472.25

Corporate Actions

Split
Ex-date: 19 Feb 2026

About Intensity

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Intensity Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$3.46
$2.60
-20.97%
Oct 2026
$3.30
$3.29
-14.55%
Sep 2026
$4.11
$3.85
-18.26%
Aug 2026
$4.25
$4.71
+12.68%
Jul 2026
$4.16
$4.18
+0.72%
Jun 2026
$4.37
$4.15
-6.74%
May 2026
$5.18
$4.45
-14.42%
Apr 2026
$5.80
$5.20
-12.16%
Mar 2026
$7.56
$5.92
-25.81%
Feb 2026
$0.36
$7.98
+2,062.60%
Jan 2026
$0.41
$0.37
-9.11%
Dec 2025
$0.38
$0.41
+2.01%

Intensity Share Price FAQs